Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 3 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 12139528

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  2. US 12139543

    Method of using an anti-epidermal growth factor receptor (EGFR) activatable antibody to detect the presence or absence of a cleaving agent and EGFR

    CytomX Therapeutics, Inc. · Granted Nov 12, 2024 · Expires Nov 7, 2044

    granted
  3. US 12128092

    Lyophilized factor IX formulations

    BIOVERATIV THERAPEUTICS INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  4. US 12129476

    Methods for measuring the potency of AADC viral vectors

    VOYAGER THERAPEUTICS, INC. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  5. US 12121567

    Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase

    Regents of the University of Minnesota · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  6. US 12116606

    Complement factor I-related compositions and methods

    Vertex Pharmaceuticals Incorporated · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  7. US 12115166

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  8. US 12104163

    Adeno-associated virus vectors for treatment of Rett syndrome

    Sarepta Therapeutics, Inc. · Granted Oct 1, 2024 · Expires Sep 26, 2044

    granted
  9. US 12091675

    Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Sep 17, 2024 · Expires Sep 12, 2044

    granted
  10. US 12077506

    Indane derivatives as hypoxia inducible factor-2(α) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  11. US 12077772

    Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1

    The Board of Regents of the University of Texas System · Granted Sep 3, 2024 · Expires Aug 29, 2044

    granted
  12. US 12071632

    Chimeric vectors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  13. US 12071468

    Purification of Factor VIII subspecies

    Takeda Pharmaceutical Company Limited · Granted Aug 27, 2024 · Expires Aug 22, 2044

    granted
  14. US 12068729

    Anti-factor XII/XIIa antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  15. US 12060566

    Self-inactivating lentiviral vector comprising a FOXP3 expression cassette

    The Regents of the University of California · Granted Aug 13, 2024 · Expires Aug 8, 2044

    granted
  16. US 12054517

    Myeloid differentiation factor 2 (MD2) signaling and modulation

    The Regents of the University of California · Granted Aug 6, 2024 · Expires Aug 1, 2044

    granted
  17. US 12049630

    Factor XII (F12) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jul 30, 2024 · Expires Jul 25, 2044

    granted
  18. US 12016932

    Gene editing for hemophilia A with improved factor VIII expression

    CRISPR THERAPEUTICS AG · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  19. US 12018259

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  20. US 12018261

    Compounds and methods for modulating factor XII

    Ionis Pharmaceuticals, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  21. US 12018027

    Macrocyclic derivatives acting as XIa factor inhibitor

    China Resources Biopharmaceutical Company Limited · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  22. US 12012438

    Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use

    The United States of America, as represented by the Secretary, Health and Human Services · Granted Jun 18, 2024 · Expires Jun 13, 2044

    granted
  23. US 12006355

    Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif)

    The Regents of the University of California · Granted Jun 11, 2024 · Expires Jun 6, 2044

    granted
  24. US 2024166750

    GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION

    ABLYNX NV [BE] · Granted May 23, 2024 · Expires May 18, 2044

    granted